NICE Infra Co., Ltd (KOSDAQ:063570)
3,270.00
0.00 (0.00%)
At close: Aug 24, 2026
NICE Infra Revenue
NICE Infra had revenue of 103.21B KRW in the quarter ending March 31, 2026, with 22.74% growth. This brings the company's revenue in the last twelve months to 403.08B, up 11.49% year-over-year. In the year 2025, NICE Infra had annual revenue of 383.95B with 13.36% growth.
Revenue (ttm)
403.08B
Revenue Growth
+11.49%
P/S Ratio
0.25
Revenue / Employee
1.04B
Employees
387
Market Cap
99.18B
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 383.95B | 45.25B | 13.36% |
| Dec 31, 2024 | 338.70B | -19.70B | -5.50% |
| Dec 31, 2023 | 358.40B | 69.49B | 24.05% |
| Dec 31, 2022 | 288.91B | 50.55B | 21.21% |
| Dec 31, 2021 | 238.36B | 12.49B | 5.53% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Sungdo Engineering & Construction | 687.67B |
| DongKoo Bio & Pharma | 241.43B |
| Paseco Co. | 160.91B |
| OPTUS Pharmaceutical | 91.62B |
| ALUX Co., Ltd. | 67.07B |
| NanoTIM | 41.12B |
| LB Investment | 34.21B |
| WOT. Co., Ltd | 20.40B |